These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 21524973

  • 1. Difference in imipenem, meropenem, sulbactam, and colistin nonsusceptibility trends among three phenotypically undifferentiated Acinetobacter baumannii complex in a medical center in Taiwan, 1997-2007.
    Liang-Yu C, Kuo SC, Liu CY, Luo BS, Huang LJ, Lee YT, Chen CP, Chen TL, Fung CP.
    J Microbiol Immunol Infect; 2011 Oct; 44(5):358-63. PubMed ID: 21524973
    [Abstract] [Full Text] [Related]

  • 2. Susceptibility of the Acinetobacter calcoaceticus-A. baumannii complex to imipenem, meropenem, sulbactam and colistin.
    Dueñas Díez AI, Bratos Pérez MA, Eiros Bouza JM, Almaraz Gómez A, Gutiérrez Rodríguez P, Miguel Gómez MA, Orduña Domingo A, Rodríguez-Torres A.
    Int J Antimicrob Agents; 2004 May; 23(5):487-93. PubMed ID: 15120728
    [Abstract] [Full Text] [Related]

  • 3. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii.
    Song JY, Kee SY, Hwang IS, Seo YB, Jeong HW, Kim WJ, Cheong HJ.
    J Antimicrob Chemother; 2007 Aug; 60(2):317-22. PubMed ID: 17540672
    [Abstract] [Full Text] [Related]

  • 4. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU.
    Sheng WH, Wang JT, Li SY, Lin YC, Cheng A, Chen YC, Chang SC.
    Diagn Microbiol Infect Dis; 2011 Jul; 70(3):380-6. PubMed ID: 21558048
    [Abstract] [Full Text] [Related]

  • 5. In vitro activities of colistin and ampicillin/sulbactam against Acinetobacter baumannii.
    Punpanich W, Munsrichoom A, Srisarang S, Treeratweeraphong V.
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S95-100. PubMed ID: 22043760
    [Abstract] [Full Text] [Related]

  • 6. Synergistic activity of sulbactam combined with colistin against colistin-resistant Acinetobacter baumannii.
    Kempf M, Djouhri-Bouktab L, Brunel JM, Raoult D, Rolain JM.
    Int J Antimicrob Agents; 2012 Feb; 39(2):180-1. PubMed ID: 22100281
    [No Abstract] [Full Text] [Related]

  • 7. Amino acid substitutions of quinolone resistance determining regions in GyrA and ParC associated with quinolone resistance in Acinetobacter baumannii and Acinetobacter genomic species 13TU.
    Liu YH, Kuo SC, Lee YT, Chang IC, Yang SP, Chen TL, Fung CP.
    J Microbiol Immunol Infect; 2012 Apr; 45(2):108-12. PubMed ID: 22153765
    [Abstract] [Full Text] [Related]

  • 8. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases.
    Tripodi MF, Durante-Mangoni E, Fortunato R, Utili R, Zarrilli R.
    Int J Antimicrob Agents; 2007 Dec; 30(6):537-40. PubMed ID: 17851050
    [Abstract] [Full Text] [Related]

  • 9. Mechanisms of resistance to ciprofloxacin, ampicillin/sulbactam and imipenem in Acinetobacter baumannii clinical isolates in Taiwan.
    Chiu CH, Lee HY, Tseng LY, Chen CL, Chia JH, Su LH, Liu SY.
    Int J Antimicrob Agents; 2010 Apr; 35(4):382-6. PubMed ID: 20138741
    [Abstract] [Full Text] [Related]

  • 10. Differences in phenotypic and genotypic characteristics among imipenem-non-susceptible Acinetobacter isolates belonging to different genomic species in Taiwan.
    Lee YT, Huang LY, Chiang DH, Chen CP, Chen TL, Wang FD, Fung CP, Siu LK, Cho WL.
    Int J Antimicrob Agents; 2009 Dec; 34(6):580-4. PubMed ID: 19733035
    [Abstract] [Full Text] [Related]

  • 11. Clonal spread of multidrug-resistant Acinetobacter baumannii in eastern Taiwan.
    Chang KC, Lin MF, Lin NT, Wu WJ, Kuo HY, Lin TY, Yang TL, Chen YC, Liou ML.
    J Microbiol Immunol Infect; 2012 Feb; 45(1):37-42. PubMed ID: 22154678
    [Abstract] [Full Text] [Related]

  • 12. In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases.
    Santimaleeworagun W, Wongpoowarak P, Chayakul P, Pattharachayakul S, Tansakul P, Garey KW.
    Southeast Asian J Trop Med Public Health; 2011 Jul; 42(4):890-900. PubMed ID: 22299471
    [Abstract] [Full Text] [Related]

  • 13. [Evaluation of the efficacy of colistin/sulbactam combination on carbapenem-resistant Acinetobacter baumannii strains].
    Çetinkol Y, Telli M, Altunçekiç Yıldırım A, Çalgın MK.
    Mikrobiyol Bul; 2016 Jul; 50(3):460-5. PubMed ID: 27525401
    [Abstract] [Full Text] [Related]

  • 14. Emergence of carbapenem resistance in Acinetobacter baumannii in the Czech Republic is associated with the spread of multidrug-resistant strains of European clone II.
    Nemec A, Krízová L, Maixnerová M, Diancourt L, van der Reijden TJ, Brisse S, van den Broek P, Dijkshoorn L.
    J Antimicrob Chemother; 2008 Sep; 62(3):484-9. PubMed ID: 18477708
    [Abstract] [Full Text] [Related]

  • 15. In vitro activities of tigecycline alone and in combination with colistin sulfate or sulbactam against carbapenem-susceptible and -resistant Acinetobacter baumannii strains isolated from Intensive Care Units.
    Ozbek B, Otük G.
    Int J Antimicrob Agents; 2010 Aug; 36(2):191-2. PubMed ID: 20537868
    [No Abstract] [Full Text] [Related]

  • 16. Molecular epidemiology, antimicrobial susceptibility and carbapenemase resistance determinants among Acinetobacter baumannii clinical isolates in Taiwan.
    Chuang YC, Sheng WH, Lauderdale TL, Li SY, Wang JT, Chen YC, Chang SC.
    J Microbiol Immunol Infect; 2014 Aug; 47(4):324-32. PubMed ID: 23726465
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of sulbactam and its combination with imipenem, colistin and tigecycline in an experimental model of carbapenem-resistant Acinetobacter baumannii sepsis.
    Dinc G, Demiraslan H, Elmali F, Ahmed SS, Metan G, Alp E, Doganay M.
    Chemotherapy; 2013 Aug; 59(5):325-9. PubMed ID: 24525528
    [Abstract] [Full Text] [Related]

  • 18. A single clone of Acinetobacter baumannii, ST22, is responsible for high antimicrobial resistance rates of Acinetobacter spp. isolates that cause bacteremia and urinary tract infections in Korea.
    Park YK, Lee GH, Baek JY, Chung DR, Peck KR, Song JH, Ko KS.
    Microb Drug Resist; 2010 Jun; 16(2):143-9. PubMed ID: 20370437
    [Abstract] [Full Text] [Related]

  • 19. Antibacterial activity of carbapenem-based combinations againts multidrug-resistant Acinetobacter baumannii.
    Pongpech P, Amornnopparattanakul S, Panapakdee S, Fungwithaya S, Nannha P, Dhiraputra C, Leelarasamee A.
    J Med Assoc Thai; 2010 Feb; 93(2):161-71. PubMed ID: 20301995
    [Abstract] [Full Text] [Related]

  • 20. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
    Timurkaynak F, Can F, Azap OK, Demirbilek M, Arslan H, Karaman SO.
    Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.